Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 37 | ECE2015 | Next issue

17th European Congress of Endocrinology

Guided Posters

Endocrine tumours and neoplasia – Adrenal Tumour

ea0037gp.29.01 | Endocrine tumours and neoplasia – Adrenal Tumour | ECE2015

Mitotane inhibits sterol-o-acyltransferase leading to lipid-mediated endoplasmic reticulum stress and apoptosis of adrenocortical carcinoma cells

Sbiera Silviu , Fassnacht Martin , Leich Ellen , Liebisch Gerhard , Schirbel Andreas , Wiemer Laura , Matysik Silke , Vanselow Jens T , Gardill Felix , Gehl Annemarie , Kendl Sabine , Beyer Melanie , Bala Margarita , Ronchi Cristina L , Deutschbein Timo , Schlosser Andreas , Schmitz Gerd , Rosenwald Andreas , Allolio Bruno , Kroiss Matthias

Context: Mitotane is the only drug approved for treatment of adrenocortical carcinoma (ACC) and in clinical use for more than 50 years. Mitotane counteracts both tumour growth and tumoral steroid hormone production but treatment is associated with severe side effects. The molecular mechanism of mitotane is still unknown, which hampers progress in treatment of ACC.Objective: To identify the mechanism of action and molecular target of mitotane.<p class...

ea0037gp.29.02 | Endocrine tumours and neoplasia – Adrenal Tumour | ECE2015

Investigation of a novel liposomal chemotherapy protocol in three preclinical models for adrenocortical carcinoma in vivo

Jung Sara , Reincke Martin , Zambetti Gerard P , Beuschlein Felix , Hantel Constanze

Recently, we demonstrated for adrenocortical carcinoma (ACC) promising antitumoural effects for LEDP-M (etoposide, liposomal doxorubicin, liposomal cisplatin, mitotane) a novel liposomal variant of the classical EDP-M protocol (etoposide, doxorubicin, cisplatin, mitotane). However, clinical translation of novel therapeutic regimens remains challenging due to high tumor heterogeneity. Thus, to obtain preclinical results with more clinically predictive power we investigated for ...

ea0037gp.29.03 | Endocrine tumours and neoplasia – Adrenal Tumour | ECE2015

Immunoexpressions of CYP11B2 and HSD3B2 in genetically characterised aldosterone producing adenomas

Gebhard Christian , Rhayem Yara , Dietz Anna , Riester Anna , Hantel Constanze , Schuster Marion , Strom Tim M , Gomez-Sanchez Celso , Reincke Martin , Beuschlein Felix

Primary aldosteronism caused by aldosterone-producing adenoma (APA) or bilateral adrenal hyperplasia is the most prevalent cause of secondary hypertension. Somatic mutations of KCNJ5, ATP1A1, CACNA1D and ATP2B3 have been shown to be involved in the formation of APA. We studied the immunoexpressions of CYP11B2 and HSD3B2, the rate-limiting enzyme for aldosterone production and the prevalent isoform of β-HSD found in APA respectively, and...

ea0037gp.29.04 | Endocrine tumours and neoplasia – Adrenal Tumour | ECE2015

Synergistic action of 9-cis retinoic acid and mitotane in a H295R adrenocortical cancer xenograft model

Nagy Zoltan , Baghy Kornelia , Szabo Peter M , Kovalszky Ilona , Perge Pal , Patocs Attila , Racz Karoly , Igaz Peter

Background: Current drug treatment options for adrenocortical carcinoma (ACC) are rather limited and intensive efforts are going on to find novel effective agents. In our previous functional genomics study, retinoid signalling via the retinoid X receptor (RXR) was identified as a major pathogenic pathway in ACC and we have demonstrated the in vitro activity of 9-cis retinoic acid (9-cisRA) acting via the RXR on NCI-H295R cells and also found that 9-cisRA has antitumou...

ea0037gp.29.05 | Endocrine tumours and neoplasia – Adrenal Tumour | ECE2015

EGFR as potential new molecular target in the medical treatment of adrenocortical cancer

Gagliano Teresa , Balboni Francesco , Pasquale Carmelina Di , Gentilin Erica , Benfini Katiusci , Falletta Simona , Bondanelli Marta , Franceschetti Paola , Feo Carlo , Uberti Ettore degli , Zatelli Maria Chiara

Adrenocortical cancer (ACC) is a rare and aggressive malignancy. Currently the main therapeutic option is surgery, but due to difficult and delayed diagnosis and to the onset of metastases, medical therapy is often tried. ACC treatment is mainly represented by Mitotane alone or in association with chemotherapy, with variable results. Understanding the molecular mechanisms that regulate ACC proliferation could be useful to identify new therapeutic options. Sunitinib, a multitar...

ea0037gp.29.06 | Endocrine tumours and neoplasia – Adrenal Tumour | ECE2015

The incidence of consecutive manifestations of VHL disease

Frantzen Carlijn , Kruizinga Roeliene C , Sluiter Wim J , de Vries Elisabeth G E , Zonnenberg Bernard A , Lips Cornelis J , Walenkamp Annemiek M E , van der Horst-Schrivers Anouk N A , Links Thera P

Background: Von Hippel Lindau (VHL) disease is a rare tumour syndrome with a high penetrance. VHL mutation carriers develop numerous disease related manifestations in multiple organs during life, but precise difference in growth velocity and incidence of lesions in different organs is still unknown. We aimed to gain insight in the incidence of consecutive new disease manifestations in the organs of patients with VHL.Patients and methods: Clinical data in...

ea0037gp.29.07 | Endocrine tumours and neoplasia – Adrenal Tumour | ECE2015

Penetrance and optimal surveillance for SDHB mutation carriers

Eijkelenkamp Karin , Osinga Thamara E , de Jong Mirjam M , Sluiter Wim J , Dullaart Robin P F , Links Thera P , Kerstens Michiel N , van der Horst-Schrivers Anouk N A

Context: Germline mutations of the gene encoding succinate dehydrogenase subunit B (SDHB) predispose to head and neck paraganglioma (HNPGL), sympathetic PGL, phaeochromocytoma and renal cell carcinoma for which regular surveillance is required. SDHB-associated tumors harbor germline and somatic mutations, consistent with Knudson’s two-hit hypothesis stating that the combination of an inactivating germline mutation as a first hit and somatic loss of funct...